Luseogliflozin
Catalog No. A13476
Luseogliflozin是由Taisho Pharmaceutical开发的一种口服活性第二代钠葡萄糖共转运蛋白2（SGLT2）抑制剂，用于治疗2型糖尿病（T2DM）患者。
| Catalog Num | A13476 |
|---|---|
| M. Wt | 434.55 |
| Formula | C23H30O6S |
| Purity | >98% |
| Storage | at -20°C 3 years Powder |
| CAS No. | 898537-18-3 |
| Synonyms | TS 071, TS071, TS-71 |
| SMILES | CCOC1=CC=C(C=C1)CC2=C(C=C(C(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](S3)CO)O)O)O)OC)C |
Luseogliflozin是由Taisho Pharmaceutical开发的一种口服活性第二代钠葡萄糖共转运蛋白2（SGLT2）抑制剂，用于治疗2型糖尿病（T2DM）患者。
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 23.01 mL | 115.06 mL | 230.12 mL |
| 0.5 mM | 4.6 mL | 23.01 mL | 46.02 mL |
| 1 mM | 2.3 mL | 11.51 mL | 23.01 mL |
| 5 mM | 0.46 mL | 2.3 mL | 4.6 mL |
*The above data is based on the productmolecular weight 434.55. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
Contact information
United StatesAdooq Bioscience
Toll Free: (866) 930-6790
Fax: +1-323-606-8156
Email: sales@adooq.com
ADOOQ 产品质量保证
We promise all products to perform as described.